Stock ALZCUR ALZECURE PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

News AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Market Closed - Nasdaq Stockholm
Other stock markets
 17:00:00 28/06/2024 BST 		5-day change 1st Jan Change
1.905 SEK -0.26% Intraday chart for AlzeCure Pharma AB +1.60% -38.75%
06-13 Alzecure Pharma AB Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain CI
05-14 AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AlzeCure decides on directed share issue to guarantor
AQ
New scientific article published on positive clinical results with Painless ACD440 against neuropathic pain
AQ
Alzecure Pharma AB Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain
CI
AlzeCure Pharma AB - Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg elected as a new board member
AQ
Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member
AQ
AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors
CI
Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2024
AQ
AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application
AQ
AlzeCure Pharma AB Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application
CI
AlzeCure Pharma publishes prospectus
AQ
AlzeCure publishes its interim report for January – March 2024
AQ
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board
AQ
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).
CI
AlzeCure Pharma publishes its Annual Report for 2023
AQ
AlzeCure presents new data regarding the TrkA-NAM pain project at IASP 2024
AQ
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024
CI
AlzeCure to partake in Redeye Theme, Alzheimer on March 21
AQ
AlzeCure to partake in Redeye Theme: Alzheimer on March 21
AQ
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALZCUR Stock
  4. News AlzeCure Pharma AB